Aerovate Therapeutics Inc (AVTE) concluded trading on Thursday at a closing price of $2.72, with 4.8 million shares of worth about $13.07 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 3115.95% during that period and on April 24, 2025 the price saw a loss of about -0.73%. Currently the company’s common shares owned by public are about 28.99M shares, out of which, 21.13M shares are available for trading.
Stock saw a price change of 1.49% in past 5 days and over the past one month there was a price change of 2898.14%. Year-to-date (YTD), AVTE shares are showing a performance of 2739.75% which increased to 239.44% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.05 but also hit the highest price of $2.86 during that period. The average intraday trading volume for Aerovate Therapeutics Inc shares is 2.67 million. The stock is currently trading 94.51% above its 20-day simple moving average (SMA20), while that difference is up 343.91% for SMA50 and it goes to 1171.25% higher than SMA200.
Aerovate Therapeutics Inc (NASDAQ: AVTE) currently have 28.99M outstanding shares and institutions hold larger chunk of about 77.63% of that.
The stock has a current market capitalization of $78.84M and its 3Y-monthly beta is at -12.51. It has posted earnings per share of -$2.45 in the same period. It has Quick Ratio of 20.93 while making debt-to-equity ratio of 0.01. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AVTE, volatility over the week remained 5.19% while standing at 4.06% over the month.
Stock’s fiscal year EPS is expected to rise by 73.14% while it is estimated to decrease by -21.27% in next year. EPS is likely to grow at an annualized rate of 34.03% for next 5-years, compared to annual growth of -77.98% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Wells Fargo on June 18, 2024 offering an Equal weight rating for the stock and assigned a target price range of between $35 and $2 to it. On June 18, 2024, Evercore ISI Downgrade their recommendations, while on June 17, 2024, Wedbush Downgrade their ratings for the stock with a price target of $3. Stock get a Neutral rating from Guggenheim on June 17, 2024.
